Boston Scientific Corp (FRA:BSX)
€ 67.5 -1 (-1.46%) Market Cap: 99.39 Bil Enterprise Value: 107.44 Bil PE Ratio: 61.18 PB Ratio: 5.37 GF Score: 84/100

Boston Scientific Corp Investor Update at HRS 2019 Transcript

May 09, 2019 / 04:00PM GMT
Release Date Price: €32.19 (-2.57%)
Susan Vissers Lisa
Boston Scientific Corporation - VP of IR

Good morning, everyone. Thank you very much for attending the Boston Scientific Investor update from the Heart Rhythm Society meeting.

Really pleased to -- we just have a few slides for you and then get deep into Q&A. I'm very pleased to have with us 4 members of our team: Joe Fitzgerald is Executive Vice President and President of Rhythm Management as well as responsibilities for our Rhythm and Neuro business segment; Ken Stein MD is our Senior Vice President and Chief Medical Officer for Rhythm Management as well as overseas global health policy for us at Boston Scientific; and then also from the Rhythm management team is Mark Bickel, who is our Vice President of Finance; and then also, please, given the overlap with the physician implanting community and electrophysiologists, we have our Vice President and General Manager for WATCHMAN from our Interventional Cardiology business, Nick Spadea-Anello.

So without further ado, we'll get right into the usual Safe Harbors apply as well as the risks factors that you can find in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot